Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitrous oxide modulator: lubeluzole.

Hans-Christoph Diener1, Thomas C Wessel

  • 1Department of Neurology, University Essen, Germany. h.diener@uni-essen.de

Current Medical Research and Opinion
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Headache·2021
Same author

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Circulation·2021
Same author

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.

Cephalalgia : an international journal of headache·2021
Same author

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Journal of arrhythmia·2021
Same author

MMW Fortschritte der Medizin·2021
Same author

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.

Annals of neurology·2021
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
See all related articles

Lubeluzole, a neuroprotective drug for acute ischemic stroke, failed to show benefits in a large trial. Despite earlier promising results, it did not outperform placebo in improving neurological outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Stroke Research

Background:

  • Acute ischemic stroke involves a cascade leading to neural damage.
  • The penumbra region is susceptible to irreversible damage.
  • Lubeluzole was investigated for its neuroprotective potential.

Purpose of the Study:

  • To evaluate the efficacy of Lubeluzole in acute ischemic stroke.
  • To assess Lubeluzole's ability to prevent neural damage and normalize excitability.

Main Methods:

  • Clinical trials, including Phase II and early Phase III, were conducted.
  • A large randomized, placebo-controlled trial formed the final assessment.

Main Results:

  • Early trials suggested improved neurological outcomes with Lubeluzole.

Related Experiment Videos

  • The final large-scale trial found no significant difference compared to placebo.

    • Conclusions:

    • Lubeluzole did not demonstrate superiority over placebo in treating acute ischemic stroke.
    • The drug's potential neuroprotective effects were not confirmed in large-scale clinical evaluation.